QuidelOrtho Posts $54M Q3 Loss, Launches $80M Restructuring and Cuts Guidance Ranges
QDEL sits 31% above its 52-week low of $9.92 on elevated volume (1.9× avg).
Summary
QuidelOrtho lost $53.8 million ($0.78/share) on $618.9M of revenue, down 12%, and launched a restructuring it says will save over $80 million a year in 2027 while narrowing 2026 guidance toward the low end.
Key Events · Earnings and Guidance · QDEL
-
Q3 Revenue Falls 12% to $618.9M
Total revenue of $618.9 million versus $699.9 million a year ago, with Point of Care down 27% on a softer respiratory season and China Labs down 45.5%. Excluding respiratory, China and U.S. Donor Screening, revenue grew 2% as reported.
-
GAAP Loss of $53.8M, Adjusted EBITDA $148M
GAAP net loss of $53.8 million, or $0.78 per diluted share; adjusted diluted EPS was $0.31. Adjusted EBITDA was $148.0 million, a 23.9% margin versus 25.3% a year ago.
-
Restructuring Targets $80M+ Annual Savings
New cost transformation and enterprise restructuring program expected to deliver over $80 million in annual savings in 2027, with approximately $30 to $35 million of one-time charges recorded in Q4 2026.
-
Two New Business Heads, COO Role Eliminated
Effective November 9, 2026, Jonathan Siegrist becomes Head of Point of Care Diagnostics and Bryan Hanson Head of Core Diagnostics, each at a $650,000 base salary plus a $650,000 retention bonus. COO Phil McLellan's employment terminates the same day.
Analysis · QDEL · Life Sciences
Revenue fell 12% to $618.9M as China pricing changes and a weak respiratory season hit the top line, prompting a restructuring that splits operations into Core Diagnostics and Point of Care Diagnostics. The program targets over $80 million in annual savings in 2027 against $30-$35 million of one-time charges in Q4 2026 — real money for a company that generated only $0.3 million of free cash flow this quarter. Guidance was narrowed toward the low end on every line, so the savings plan is now the main lever for the 2027 earnings story, and the COO role was eliminated outright.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QDEL was trading at $13.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $966.2M. The 52-week trading range was $9.92 to $35.58. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.